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Abstract
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Purpose—The use of electronic cigarettes (e-cigarettes) has risen dramatically in recent years.
However, there is currently no published data on use of e-cigarettes among cardiac patients. The
current study reports on the prevalence, reasons for use, and perceived risks of e-cigarettes among
post-Acute Coronary Syndrome (ACS) patients. The relationship between e-cigarette use and postACS tobacco smoking cessation is also explored.
Methods—Participants were drawn from a randomized trial of smoking cessation treatments
following hospitalization for ACS. The current study focuses on 49 participants that completed ecigarette questions at 24 weeks post-ACS.
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Results—51.0% of participants reported ever use of an e-cigarette and 26.5% reported using an
e-cigarette at some time during the 24 weeks post-ACS. Ever use and post-ACS use were both
significantly associated with lower rates of abstinence from tobacco cigarettes. Participants
perceived e-cigarettes as less harmful to cardiac health than tobacco use and Chantix, and similarly
harmful as nicotine replacement therapy. Participant perceived likelihood of experiencing a heart
attack in the next year was 34.6% if they were to regularly use e-cigarettes only, significantly
lower than perceived risk of recurrence if they were to regularly smoke only tobacco cigarettes
(56.2%) and significantly higher than perceived risk of recurrence if they were to use no nicotine
(15.2%).
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Conclusions—A significant minority of patients are using e-cigarettes post-ACS. Providers
should be prepared to discuss potential discrepancies between patient beliefs about the safety of ecigarettes and the current state of the science.
Keywords
Electronic cigarettes; acute coronary syndrome; smoking
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Electronic cigarettes (e-cigarettes) are battery-powered devices that deliver an inhaled
aerosol that typically contains nicotine, flavorants, and propylene glycol and/or vegetable
glycerin. They do not contain tobacco, require combustion, or produce smoke or carbon
monoxide. While the prevalence of smoking traditional tobacco cigarettes has decreased
over the past decade, use of e-cigarettes has risen. Between 2010 and 2013 both ever use
(rose from 3.3% to 8.5%) and current use (rose from 1.0% to 2.6%) of e-cigarettes doubled
among US adults1. Current and former tobacco cigarette use are the strongest predictors of
e-cigarette use1, 2. 37% of current tobacco cigarette smokers have ever used an e-cigarette
and 9.4% are current e-cigarette users1, 3.
Current smokers perceive electronic cigarettes to be significantly less harmful and less likely
to cause health problems compared to tobacco cigarettes, including the perception that ecigarettes are less likely to cause heart disease4. It may be the case that e-cigarettes present
significantly lower cardiac risk compared to combustible cigarette use, but only preliminary
data is available on this topic5.
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Some data exists on the prevalence of e-cigarette use in medical patients who smoke with
estimates of current use ranging from 18–27%6–9. To our knowledge, no data exists
regarding 1) prevalence, reasons for use, or perceived risks of e-cigarettes or 2) the
relationship between e-cigarette use and cessation of tobacco cigarettes specifically among
patients with cardiovascular disease. The current study provides data on these issues in a
sample of post-Acute Coronary Syndrome (ACS) patients participating in a smoking
cessation trial.

Methods
Participants
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Participants in the current study were drawn from participants in a randomized trial of
smoking cessation treatments following ACS (NCT01964898). For the parent trial, we
recruited patients that: 1) had an ACS diagnosis documented in their medical record
(diagnosis of unstable angina, ST elevation myocardial infarction, or non-ST elevation
myocardial infarction), 2) smoked ≥ 3 tobacco cigarettes per day, 3) were between the ages
of 18–75, 4) were fluent in English, 5) had regular access to a telephone, 6) lived within a
one hour drive of their admitting hospital, and 7) were willing to “strongly consider” an
attempt to quit smoking at discharge. Patients were excluded if they: 1) evidenced limited
mental competency, 2) presented with psychosis, serious mental illness, or suicidality, 3)
were not expected to live through the study period or 4) were regularly attending counseling
for depression or smoking cessation and planned to continue after hospital discharge.
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Patients who smoked ≥ 3 cigarettes per day who also used other tobacco products (e.g.,
cigars, pipe) or e-cigarettes were allowed to participate.
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All participants received smoking cessation counseling during their inpatient stay for ACS
consistent with the most recent national guidelines10. Subsequently, participants were
randomly assigned to receive an integrated smoking cessation and mood management
counseling program or mailed smoking cessation educational materials over 12 weeks after
hospital discharge. Both conditions were offered an 8-week supply of nicotine patches at
hospital discharge. Neither treatment specifically encouraged or discouraged e-cigarette use.
If participants asked about safety of the e-cigarettes or about using them as a way to quit
smoking, study staff responded that there was not enough evidence on the safety or efficacy
of e-cigarettes for our team to recommend their use. This approach was consistent with the
state of e-cigarette research when this protocol was designed in 2011 and is also consistent
with the current literature11, 12.
Participants were assessed by staff members while in the hospital following ACS and at 12
and 24 weeks post-discharge. The current study focuses on e-cigarette questions asked at the
24-week post-discharge assessment, thus we only report on trial participants that completed
this assessment. All procedures were approved by The Miriam Hospital institutional review
board.
Measures
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At baseline participants self-reported demographics and smoking variables (including the
Fagerström Test for Cigarette Dependence13 and their confidence in ability to quit smoking
rated 0–10), and medical history was pulled from clinical charts. At the 24-week assessment,
patients self-reported if they had attended any cardiac rehabilitation or smoked tobacco
cigarettes since hospital discharge. Seven-day point prevalence abstinence from tobacco
cigarettes was established by exhaled carbon monoxide (eCO<10ppm) at the 24-week
assessment.
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All e-cigarette questions were asked at the 24-week assessment. Participants were asked if
they had “ever used an e-cigarette or vapor device, even one or two times.” We included
“vapor devices” to ensure that patients included use of so called “second” or “third
generation” e-cigarette products which are known by a variety of terms (e.g., “hookah pens,”
“tank systems,” “mods,”) and often look more like large fountain pens than a cigarette.
Those who endorsed ever use reported date of first use, if they had used since discharge
from the hospital, and why they tried e-cigarettes for the first time (responses were coded by
the assessor into one of 15 categories; e.g., “to cut down on other tobacco,” “curiosity,” or
“to save money”).
Those who reported ever use also reported on the relative perceived harmfulness of ecigarettes. Specifically, participants were asked to rate e-cigarettes, the nicotine patch, the
nicotine gum, the nicotine lozenge, smokeless tobacco, Chantix, and Zyban/Wellbutrin on
harmfulness to cardiac health on a scale from 0–10, where 0 = “not at all harmful,” and 10 =
“extremely harmful.” If participants had never heard of a product or did not know anything
about it, they did not rate harmfulness of that product. In addition, participants were asked to
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rate from 0–100% “How likely are you to have a heart attack in the next year” if you were to
1) “regularly smoke only tobacco cigarettes?,” 2) “regularly use e-cigarettes or vapor devices
only?,” or 3) “quit all nicotine products?”

Results
49 participants completed the questionnaire regarding e-cigarette use at 24 weeks post-ACS.
The demographics, smoking history, and medical history of these participants are presented
in Table 1.

Author Manuscript

51.0% (n=25) of participants reported ever use of an e-cigarette. 28.6% (n=14) reported first
use before ACS, and 22.4% (n=11) reported first use post-ACS. 26.5% (n=13) reported
using an e-cigarette at some time during the 24 weeks post-ACS. The most common reasons
for trying an e-cigarette were “used to quit other tobacco” (60.0%; n=15), “used to cut down
on other tobacco” (16.0%; (n=4)), and “curiosity” (28.0%; n=7). No other reason was
endorsed by ≥ 10% of the sample (data not presented).
Of those who reported post-ACS use (n=13), 76.9% (n=10) reported lapsing to tobacco
cigarettes prior to using an e-cigarette, 15.4% (n=2) used an e-cigarette prior to lapsing to
tobacco cigarettes, and 7.7% (n=1) never lapsed to tobacco cigarettes following ACS. 12.2%
(n=6) of all participants reported using an e-cigarette in the 30 days prior to the 24-week
assessment.
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Participants that had ever used an e-cigarette were significantly less likely to be abstinent
from tobacco cigarettes at 24 weeks (28.0% vs. 70.8%; X2 (1, N = 49) = 8.99, p = .003) and
to have maintained continuous abstinence post-ACS (16.0% vs. 58.3%; X2 (1, N = 49) =
9.44, p = .002) than those who had never used an e-cigarette. At baseline, participants that
had ever used an e-cigarette also reported significantly more lifetime quit attempts
(U=172.0, p=.01) and significantly lower confidence in their ability to quit (t(47)=2.2, p=.
04) than those who had never used an e-cigarette.
Those that used e-cigarettes during the 24 weeks post-ACS were significantly less likely to
be abstinent from tobacco cigarettes at 24 weeks (23.1% vs. 58.3%; X2 (1, N=49)=4.75, p
= .03), to have maintained continuous abstinence (7.7% vs. 47.2%; Fisher exact test p = .02),
and to accept free nicotine patches provided by the research study (61.5% vs. 91.7%; Fisher
Exact test p = .02) than those who did not. At baseline, participants that used e-cigarettes
during the 24 weeks post-ACS also reported significantly more lifetime quit attempts (U =
143.5; p = .04) and significantly lower confidence in their ability to quit (t(47)=2.1, p=.04)
than those who did not.
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Figure 1 shows participant perceived harm to cardiac health by product among ever users.
Participants rated e-cigarettes as significantly less harmful to their cardiac health than
regular tobacco cigarettes (paired t(24) = 10.52, p <.001), smokeless tobacco (paired t(22) =
7.89, p <.001), and Chantix (paired t(21) = 2.85, p = .01) and similarly harmful as the
nicotine patch, gum, and lozenge. Participants rated Zyban/Wellbutrin as somewhat more
harmful than e-cigarettes, but this difference was not significant.
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Participant perceived likelihood of experiencing a heart attack in the next year was 56.2%
(SD = 28.3%) if they were to regularly smoke only tobacco cigarettes, 34.6% (SD = 27.3%)
if they were to regularly use e-cigarettes or vapor devices only, and 15.2% (SD = 13.4%) if
they were to quit all nicotine products. Participants perceived that using e-cigarettes would
significantly increase the odds of a heart attack relative to no nicotine use (paired t (24)=
4.59, p <.001), but significantly decrease the odds of a heart attack relative to tobacco
cigarette use (paired t (24)= 3.87, p = .001).

Discussion

Author Manuscript

Little is known regarding e-cigarette use among cardiovascular disease patients. This study
is the first to address this gap in the literature. More than half of the sample reported ever
using an e-cigarette and just over 12% endorsed current use. Most interestingly, 26.5% of
our sample reported using an e-cigarette at some time during the 24 weeks post-ACS and
22.4% reported using an e-cigarette for the first time post-ACS.
Although mixed, the current extant literature favors e-cigarettes helping smokers quit
tobacco14. Thus, it was interesting that both ever and post-ACS e-cigarette use was
associated with lower rates of point prevalence and continuous abstinence from tobacco
cigarettes. We cannot conclude from this data that e-cigarette use caused relapse, particularly
because the vast majority of post-ACS e-cigarette users relapsed to tobacco cigarettes prior
to using an e-cigarette. Further, both ever and post-ACS e-cigarette users reported lower
confidence in their ability to quit smoking and a greater number of previous failed quit
attempts at baseline which further obscures causality.
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Consistent with previous research15, e-cigarettes were rated as less harmful than tobacco
products and prescription cessation medications, and similarly harmful as nicotine
replacement therapies. It is difficult to evaluate the accuracy of these perceived differences
in safety given that data on the safety of e-cigarettes is still emerging. However, existing data
suggest that patients are likely accurate in their perception that e-cigarettes are less harmful
that tobacco products, but may be inaccurate in their perception that e-cigarettes are
similarly (in the case of nicotine replacement therapies) or less harmful (in the case of
prescription cessation medications) than FDA approved medications.
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When asked specifically about one year heart attack risk, participants reported that exclusive
use of e-cigarettes would reduce risk relative to tobacco use, which is consistent with
perceptions of general cardiac harm. However, participants also reported that e-cigarettes
significantly increased the risk of heart attack relative to no nicotine use, suggesting that
even e-cigarette users believe e-cigarettes have some risk.
These findings have implications for providers, particularly cardiac rehabilitation programs
which aim to provide comprehensive patient health education post-ACS. National guidelines
for rehabilitation16 emphasize the importance of smoking as a risk factor, but do not yet
provide guidance regarding e-cigarettes. The current data indicates that about a quarter of
smoking patients are using e-cigarettes post-ACS. Thus, rehabilitation providers should
routinely assess e-cigarette use (particularly among smokers and recent quitters). Providers
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should also be prepared to educate patients regarding e-cigarettes and discuss potential
discrepancies between patient beliefs about the safety of e-cigarettes and the current state of
the science. The American Heart Association recently released a policy statement on the use
of e-cigarettes11 (which is generally consistent with the current policy statements of other
groups12) that should guide efforts to address e-cigarette use among post-ACS patients. Key
conclusions of this statement include 1) that there is currently insufficient evidence “for
clinicians to counsel their patients who are using tobacco products to use e-cigarettes as a
primary cessation aid” and 2) “If a patient has failed initial treatment, has been intolerant to
or refuses to use conventional smoking cessation medication, and wishes to use e-cigarettes
to aid quitting, it is reasonable to support the attempt.” Given that many post-ACS patients
do not attend rehabilitation, it is important that other post-ACS providers can also provide
the above education.
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This study has some limitations. In particular, the prevalence rates of e-cigarette use among
ACS patients reported in this study should be interpreted within the context of our modest
sample size and known regional differences in prevalence rates8. Second, we did not
distinguish between generations of e-cigarettes in our survey (a limitation because recent
research has shown substantial differences between generation, including nicotine dose and
effectiveness for smoking cessation; e.g.,15) or collect data on frequency of e-cigarette use.
Future work should address these limitations and explore methods of educating both
providers and ACS patients regarding e-cigarettes.
Conclusion
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A significant minority of patients are using e-cigarettes post-ACS. Post-ACS patients believe
that e-cigarettes are similarly or less harmful than FDA approved medications. Providers
should be prepared to discuss potential discrepancies between patient beliefs about the
safety of e-cigarettes and the current state of the science.
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Figure 1.
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Author Manuscript
Author Manuscript
Author Manuscript
J Cardiopulm Rehabil Prev. Author manuscript; available in PMC 2017 September 01.

Author Manuscript

Author Manuscript
30.6%

4.0%

2.0%

36.7%
10.2%

NSTEMI

Unstable angina

J Cardiopulm Rehabil Prev. Author manuscript; available in PMC 2017 September 01.
38.9 ± 11.6
4.8 ± 2.2
3.0 [4.0]
7.3 ± 2.6

Total years smoking tobacco cigarettes regularly

FTCD

Median number of 24-hour quit attempts in lifetimea,b

Confidence in ability to quit (rated 1–10)a,b

49.0%
83.7%

Randomized to mood management condition

Accepted free nicotine patches offered by studyb

Treatment Process and Outcome

17.0 ± 9.2

Tobacco, cigarettes/day

Baseline Smoking Variables

53.1%

32.7%

51.0%

38,000 [54,675]

STEMI

Type of ACS index event

Prior ACS event

Medical History

Some college education

Median yearly household income, $

Employed full or part-time

57.1%

2.0%

Hispanic Caucasian

Multiracial

4.0%

6.1%

African American

80.0%

48.0%

6.6 ± 2.8

5.0 [8.0]

5.1 ± 2.1

38.5 ± 11.9

15.9 ± 8.6

8.0%

32.0%

60.0%

36.0%

64.0%

44,000 [42,250]

52.0%

4.0%

89.8%

88.0%

40%

56.0%

56.0 ± 11.1

Ever-Used E-Cigarette
(n = 25)

Non-Hispanic Caucasian

Race

59.2%

Female

56.5 ± 10.6

Married or living with committed partner

Age, y

Demographics

Total (n = 49)

87.5%

50.0%

8.1 ± 2.2

2.0 [2.0]

4.6 ± 2.2

39.3 ± 11.4

18.2 ± 9.9

12.5%

41.7%

45.8%

29.2%

37.5%

27,000 [51,400]

62.5%

0.0%

0.0%

8.3%

91.7%

20.8%

62.5%

57.1 ± 10.3

Never Used E-Cigarette
(n = 24)

Author Manuscript

Participant Characteristics By E-Cigarette Use
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36.7%

Continuous abstinence from tobacco at 24 weeks post-ACSa,b
16.0%

28.0%

32.0%

58.3%

70.8%

41.7%

7.7%

23.1%

30.8%

E-Cigarette Use PostACS (n = 13)

47.2%

58.3%

38.9%

No E-Cigarette Use
Post-ACS (n = 36)

b

Post-ACS users differ from post-ACS non-users; P < .05.

Ever-users differ from never-users; P < .05.

a

Abbreviations: ACS, acute coronary syndrome; STEMI, ST segment elevation myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction; FTCD, Fagerström Test for Cigarette
Dependence; eCO, exhaled carbon monoxide. Data presented as either mean SD, median [IQR] or %.
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24 weeks post-ACSa,b

Attended cardiac rehabilitation post-ACS
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(n = 24)
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